Welcome to SAfAIDS
The International Conference on AIDS and STI’s in Africa (ICASA) 2015 was scheduled to be hosted in Hammamet in Tunisia as determined after a successful bid process. This was slated to be the largest bilingual gathering of AIDS and STI stakeholders in Africa. However the board of Society for AIDS in Africa (SAA) took a rather difficult decision due to security concerns and circumstances beyond our control to move the conference to an alternative venue. The recent trip of the SAA board in Zimbabwe has been successful and we are pleased to announce that Zimbabwe will welcome all delegates including key populations at ICASA 2015.
HARARE, 29 July 2015 (ARASA) - During the 2014 Annual Partnership Forum, Zimbabwe was identified as the focus country for the roll-out of the ARASA-supported HIV, TB and Human Rights Capacity Strengthening and Advocacy Country Programme in 2014. SAfAIDS and the Zimbabwe Network of People Living with HIV (ZNNP+) were selected to co-host the Country Programme.
GENEVA, 28 July 2015 (allAfrica) - Everyone confirmed HIV positive should receive drug treatment immediately after diagnosis, according to upcoming guidelines by the World Health Organization (WHO). These would bring the number of people eligible for treatment from about 28 to 37 million worldwide - although only about 15 million people are actually receiving treatment.
GENEVA, 27 July 2015 (allAfrica) - The Global Fund partnership recognizes that a vigorous debate about international investment in global health is important, including scrutiny and questioning by the news media. But facts matter.
GABORONE, 23 July 2015 (allAfrica) - On Thursday, 23 July 2015, the Botswana Court of Appeal will hear arguments in an appeal against a 2014 High Court judgment in which the government was ordered the provide HIV-positive foreign prisoners with antiretroviral (ARV) treatment.
PRETORIA, 22 July 2015 (allAfrica) - Results of two large medicine trials, known as START and TEMPRANO, published this week show that the health of people with HIV will benefit from starting antiretroviral treatment earlier. These findings are a climax of a bit more than four decades of research on this relatively new disease.